926,379 Shares in Boston Scientific Corporation $BSX Acquired by PFA Pension Forsikringsaktieselskab

PFA Pension Forsikringsaktieselskab acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 926,379 shares of the medical equipment provider’s stock, valued at approximately $88,942,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares in the last quarter. Rathbones Group PLC boosted its holdings in shares of Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares in the last quarter. Synergy Asset Management LLC boosted its holdings in shares of Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after purchasing an additional 479,593 shares in the last quarter. Gladstone Institutional Advisory LLC boosted its holdings in shares of Boston Scientific by 39.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after purchasing an additional 14,700 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at $26,955,000. Institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Institutional interest: hedge fund Lone Pine (Stephen Mandel) recently opened a new position in BSX, signaling some large investors view recent weakness as a buying opportunity. Stephen Mandel Opens New Position
• Positive Sentiment: Analyst conviction persists in places: media pieces note that the average brokerage recommendation still favors adding BSX — analysts continue to highlight long‑term fundamentals despite recent headwinds. Wall Street Analysts Think Boston Scientific Is a Good Investment
• Neutral Sentiment: Investor attention and commentary: several outlets (Zacks, MSN, Yahoo) are amplifying debate about BSX’s outlook — this increases short‑term volatility but is informational rather than a direct catalyst. Zacks: Attracting Investor Attention
• Negative Sentiment: Mounting securities‑class‑action notices and lead‑plaintiff deadlines (May 4) from multiple law firms are creating legal risk and headline pressure; numerous firms are soliciting plaintiffs and investigating potential misstatements about market growth/competition. This is likely a near‑term overhang. PR Newswire: Opportunity to Lead Securities Fraud Lawsuit Faruqi & Faruqi Reminder
• Negative Sentiment: Analyst downgrades and price‑target cuts: several firms have trimmed targets (Argus cut its PT to $95; other outlets report an ~11% PT reduction to ~$90 and Daiwa moved BSX from strong‑buy to hold). Those revisions reflect the company’s recent guidance/earnings and rising competitive pressures and are weighing on sentiment. Argus Price Target Cut Price Target Reduced

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Down 1.7%

Shares of NYSE:BSX opened at $56.64 on Friday. The firm has a market cap of $84.18 billion, a P/E ratio of 23.70, a P/E/G ratio of 1.06 and a beta of 0.78. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12-month low of $56.05 and a 12-month high of $109.50. The business has a fifty day simple moving average of $67.06 and a 200 day simple moving average of $84.72.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the company earned $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Evercore reduced their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. UBS Group reduced their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Robert W. Baird reduced their target price on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating on the stock in a report on Thursday, April 23rd. Morgan Stanley reduced their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Finally, Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.